Liyang Wu
Impact in
- Virology top 10%
- HIV Research and Treatment
- Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
Papers in
- Co-authors
- Hui Zhang (5 shared papers)Ting Shuang Pan (4 shared papers)Peng Zhang (5 shared papers)Mo Zhou (2 shared papers)Xiancai Ma (3 shared papers)Xiaoping Tang (3 shared papers)Guiming Liu (3 shared papers)Linghua Li (3 shared papers)
- Journals
- Urology (2 papers)Journal of Virology (2 papers)eLife (2 papers)Brazilian Journal of Medical and Biological Research (1 paper)International Journal of Oncology (1 paper)
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Liyang Wu
34 papers receiving 825 citations
Liyang Wu's Hit Papers
Peers
Comparison fields: 5 of 44
- Virology 79
- Infectious Diseases 276
- Urology 43
- Immunology 39
- Molecular Biology 82
Countries citing papers authored by Liyang Wu
This map shows the geographic impact of Liyang Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liyang Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liyang Wu more than expected).
Fields of papers citing papers by Liyang Wu
This network shows the impact of papers produced by Liyang Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liyang Wu. The network helps show where Liyang Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Liyang Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι Hit paper breakdown → | 2021 | 389 |
| 2 | 2019 | 92 | |
| 3 | 2018 | 53 | |
| 4 | 2021 | 38 | |
| 5 | 2022 | 29 | |
| 6 | 2021 | 28 | |
| 7 | 2019 | 25 | |
| 8 | 2019 | 18 | |
| 9 | 2016 | 16 | |
| 10 | 2018 | 14 | |
| 11 | Expression of bone morphogenetic protein-10 (BMP10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro. | 2013 | 13 |
| 12 | 2019 | 13 | |
| 13 | 2020 | 13 | |
| 14 | 2019 | 10 | |
| 15 | 2020 | 10 | |
| 16 | 2022 | 10 | |
| 17 | Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma. | 2014 | 9 |
| 18 | 2013 | 7 | |
| 19 | 2018 | 7 | |
| 20 | 2016 | 6 |
About Liyang Wu
Liyang Wu is a scholar working on Urology, Virology, Transplantation, Infectious Diseases and Radiology, Nuclear Medicine and Imaging, having authored 37 papers that have together received 841 indexed citations. Recurring topics across this work include Urinary Bladder and Prostate Research (10 papers), HIV Research and Treatment (6 papers), Angiogenesis and VEGF in Cancer (3 papers), Hepatitis B Virus Studies (2 papers), Radiomics and Machine Learning in Medical Imaging (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Neurological Disease Mechanisms and Treatments (1 paper) and Mosquito-borne diseases and control (1 paper). The work is most often cited by research in Virology (79 citations), Infectious Diseases (276 citations), Urology (43 citations), Immunology (39 citations) and Molecular Biology (82 citations). Liyang Wu has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Hui Zhang, Ting Shuang Pan, Peng Zhang, Mo Zhou, Xiancai Ma, Xiaoping Tang, Guiming Liu, Linghua Li, Wen G. Jiang and Lin Ye. Their work appears in journals such as Urology, Journal of Virology, eLife, Brazilian Journal of Medical and Biological Research and International Journal of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.